+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 6Months - 30Years
All Genders
ID05533775

Evaluating Glofitamab Alone and With Chemoimmunotherapy for Children and Young Adults With RelapsedRefractory Mature B-Cell Non-Hodgkin Lymphoma

Led by Hoffmann-La Roche · Updated on 2026-10-06

65

Participants Needed

30

Research Sites

156 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effects of glofitamab, alone and combined with a standard chemoimmunotherapy regimen rituximab, ifosfamide, carboplatin, and etoposide - R-ICE, in children and young adults with relapsed or refractory mature B-cell non-Hodgkin lymphoma. This study includes participants aged from 6 months to under 30 years with confirmed aggressive B-cell lymphoma that expresses CD20 and who have had prior treatments that were ineffective or intolerable. Participants are assigned to one of two treatment groups one receives glofitamab combined with R-ICE chemotherapy for up to three 21-day cycles, and the other receives glofitamab alone for up to twelve 21-day cycles. Additional drugs like obinutuzumab, rituximab, and tocilizumab for managing side effects are also given intravenously according to specified schedules. The study monitors treatment effects over several cycles and includes detailed dosing days for each medication within the 21-day treatment cycles. During the study, participants undergo assessments for tumor response, side effects, and drug levels in the blood. Researchers use imaging and clinical criteria to evaluate complete responses and other outcomes, with follow-up periods extending up to approximately four years depending on the treatment arm. Safety is monitored continuously, and participants health status is assessed regularly throughout the treatment and follow-up periods.

CONDITIONS

Brief Title

A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma

Research Team

R

Reference Study ID Number: CO43810 https://forpatients.roche.com/ No attachments to email below.

F

Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here